Analysis Tools
mortality/aging
|
• mice die at E10.5 to E11.5
|
|
Allele Symbol Allele Name Allele ID |
Men1tm1.1Ctre targeted mutation 1.1, Judy S Crabtree MGI:2158698 |
||||||||||||||||||||||||||||||||||||||||
| Summary |
9 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice die at E10.5 to E11.5
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• after 9 months, 83% of mice develop pancreatic islet tumors unlike wild-type mice
• pancreatic tumors begin at a slightly earlier age than in Men1tm1Ctre heterozygotes
|
|
• after 9 months, 83% of mice develop pancreatic islet tumors unlike wild-type mice
• pancreatic tumors begin at a slightly earlier age than in Men1tm1Ctre heterozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop tumors of the pituitary, thyroid, parathyroid, pancreas, adrenal and testis
|
|
• lung adenomcarcinomas develop in 42% of mice including 2 neuroendocrine carcinomas
• tumors have several nodules and individual nodules consisting of more than one tumor cell type with blurred or disrupted borders
• bronchioalveolar stem cells are expanded in lung tumors
|
|
• lung adenomcarcinomas develop in 42% of mice including 2 neuroendocrine carcinomas
• tumors have several nodules and individual nodules consisting of more than one tumor cell type with blurred or disrupted borders
• bronchioalveolar stem cells are expanded in lung tumors
|
|
• mice develop tumors of the pituitary, thyroid, parathyroid, pancreas, adrenal and testis
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice exhibit adrenal cortical tumors (28%)
|
|
• in 44% of mice
|
|
• 57% of mice exhibit pancreatic islet adenomas
|
|
• 61% of mice exhibit parathyroid adenomas
|
|
• mice exhibit pituitary anterior lobe tumors (81%)
|
|
• 6% of mice exhibit lung metastasis
|
|
• 6% of mice exhibit lung metastasis
|
|
• mice exhibit adrenal cortical tumors (28%)
|
|
• in 44% of mice
|
|
• 57% of mice exhibit pancreatic islet adenomas
|
|
• 61% of mice exhibit parathyroid adenomas
|
|
• mice exhibit pituitary anterior lobe tumors (81%)
|
|
• mice exhibit pituitary anterior lobe tumors (81%)
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop tumors of the pituitary, thyroid, parathyroid, pancreas, adrenal and testis
|
|
• in 6 % of mice
|
|
• in 6 % of mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• no viable double homozygous embryos were present beyond E15.5
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median lifespan is 402 days compared to 546 days for Men1tm1.1Ctre heterozygotes
|
|
• adrenal cortical tumor (10% of mice)
|
|
• in 45% of mice
|
|
• 55% of mice exhibit pancreatic islet tumors
|
|
• 50% of mice exhibit parathyroid gland tumors
|
|
• mice exhibit pituitary anterior lobe tumors (40% of mice)
|
|
• pituitary intermediate lobe tumors (96% of mice)
|
|
• mice exhibit thyroid C-cell carcinomas (96%)
|
|
• metastasis in the lungs (70% of mice)
|
|
• mice exhibit pituitary anterior lobe tumors (40% of mice)
|
|
• pituitary intermediate lobe tumors (96% of mice)
|
|
• adrenal cortical tumor (10% of mice)
|
|
• in 45% of mice
|
|
• 55% of mice exhibit pancreatic islet tumors
|
|
• 50% of mice exhibit parathyroid gland tumors
|
|
• mice exhibit pituitary anterior lobe tumors (40% of mice)
|
|
• pituitary intermediate lobe tumors (96% of mice)
|
|
• mice exhibit thyroid C-cell carcinomas (96%)
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• some mice exhibit Leydig cell adenocarcinomas
|
|
|
• some mice exhibit Leydig cell adenocarcinomas
|
|
• some mice exhibit Leydig cell adenocarcinomas
|
|
• most lung tumors are primary
• bronchioalveolar stem cells are expanded in lung tumors compared to in Cdkn2ctm1Yxi homozygotes or Men1tm1.1Ctre heterozygotes
|
|
• in 33% of mice before 1 year of age
|
|
• after 1 year of age, lung adenocarcinomas develop in 63% of mice including 3 carcinomas with neuroendocrine characteristics
• mice develop multiple lung carcinomas that are more aggressive and invasive than in single mutant mice
• neuroendocrine carcinomas are more proliferative and apoptotic than in single mutant mice
|
|
• tumors develop quicker than in Men1tm1.1Ctre heterozygotes
|
|
|
• some mice exhibit Leydig cell adenocarcinomas
|
|
|
• some mice exhibit Leydig cell adenocarcinomas
|
|
• most lung tumors are primary
• bronchioalveolar stem cells are expanded in lung tumors compared to in Cdkn2ctm1Yxi homozygotes or Men1tm1.1Ctre heterozygotes
|
|
• in 33% of mice before 1 year of age
|
|
• after 1 year of age, lung adenocarcinomas develop in 63% of mice including 3 carcinomas with neuroendocrine characteristics
• mice develop multiple lung carcinomas that are more aggressive and invasive than in single mutant mice
• neuroendocrine carcinomas are more proliferative and apoptotic than in single mutant mice
|
|
|
• some mice exhibit Leydig cell adenocarcinomas
|
|
|
• some mice exhibit Leydig cell adenocarcinomas
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• no viable double homozygous embryos were present beyond E15.5
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 08/21/2024 MGI 6.24 |
|
|
|
||